SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MGNX -- MacroGenics
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
188 21 0 MGNX
Emcee:  scaram(o)uche Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
138Hey Toly! Ugh, world sucks! Check out the weather in Kenosha. Currently minusscaram(o)uche-1/26/2019
137Clinical hold lifted with about 2-minute volume and share price spike then settlhmpa-1/26/2019
136Like with NKTR, OppenheimerFunds is optimistic here as well (10% stake): secfiliMiljenko Zuanic-1/19/2019
135likely no direct benefit to mgnx........ Clin Cancer Res. 2019 Jan 17. pii: cliscaram(o)uche-1/19/2019
134CFO, K James, also hold his share. Not a surprise, who will sell at "depresMiljenko Zuanic-1/11/2019
133RE: Margetuximab In light of the imminent read-out of the SOPHIA PFS-end point, Miljenko Zuanic-1/11/2019
132Marget: P3, changes in PFS -end pots time-table, requirement for analysis reacheMiljenko Zuanic-1/10/2019
131K. Scott feel positive with options exercise and hold, but for how long??? secfiMiljenko Zuanic-1/8/2019
130clinicaltrials.gov Margetuximab SOPHIA trial, 200 centers is involved for 3 yearMiljenko Zuanic-12/28/2018
129Me too, but I do believe that the trials will restart. The Evaluate article wasscaram(o)uche-12/27/2018
128Yes, all point that it is CD3 engagement. Severity, time-concentration, and doesMiljenko Zuanic-12/27/2018
127Thanks! But I don't understand. If it's CRS (passive toxicity), then iscaram(o)uche-12/27/2018
126evaluate.com Enoblituzumab (B7-H3) was/is not on clinical hold, so it is not taMiljenko Zuanic-12/10/2018
125IF DARTs are dead, why Roche give them FREE MONEY?Miljenko Zuanic-12/10/2018
124009 was not 25% of the EV. Sell-off is severe...............Miljenko Zuanic-12/10/2018
123Clinical hold on 009 and combos thereof: MGD009 hold Cheers, Tucktuck-12/7/2018
122Thanks. On surface both compounds appear similar on activity. I do not know muchMiljenko Zuanic-12/4/2018
121snippets from a couple of ASH abstracts..... Message 31913838scaram(o)uche-12/4/2018
120Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refrMiljenko Zuanic-12/3/2018
119This is how you do license in oncology, $300m upfront, 50/50 US, +20% ex-US,... Miljenko Zuanic-12/3/2018
118Also, this is, somehow, *red flag* signal that MGNX is not very comfortable withMiljenko Zuanic-11/29/2018
117>> You think they will know what is net sales? << Yes. >> IFscaram(o)uche-11/29/2018
116"on annual net sales of the assets, which may be subject to adjustment in sMiljenko Zuanic-11/29/2018
115"double digit royalties".... we certainly could use some more coloscaram(o)uche-11/29/2018
114finance.yahoo.com Another F. Idiots that are handling drug candidates to China,Miljenko Zuanic-11/29/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News